Back to top

Takeda Advances Pediatric Pouchitis Trial, Extending Entyvio’s Long???Term Growth Story

Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Takeda (TAK) is running a Phase 3 study called “An Open-l...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Takeda Pharmaceutical Co. (TAK)